and dropping 16% for its worst day since May of 2021. The company discontinuing development of its drug to treat a type of chronic sanitis after it failed to meet primary and secondary end points in trial. That drug had been cleared by the FDA to treat a serious chronic lung disease in August of this year.Even with today's move in shares are up 141% year to date. It's still among the most valuable biotech stocks with a market cap of more than $ 35 billion. For more, Missouo healthcare strategist Jared Holes ...